Qiongding Medical Secures Nearly RMB 100 Million Series A+ Funding to Advance Non-Invasive Deep Brain Neuromodulation Platform

At the Start of 2026, as the Global Race in Brain Science and Brain-Inspired Research Intensifies, a Major Breakthrough Emerges in China’s Therapeutic Brain-Computer Interface Field: Neurodome, Inc. (referred to as "Neurodome"), a pioneering innovator specializing in non-invasive deep-brain precision neuromodulation technology, has successfully completed nearly RMB100 million in its Series A+ funding round. This round was led by Mingxi Capital, with participation from Optics Valley Industrial Investment. Existing shareholders Shunwei Capital, Huafang Capital, iFlytek Ventures, and Oriza Origins continued their support, while Chasing Beyond served as the exclusive financial advisor. The proceeds from this financing will provide strong momentum for Neurodome to accelerate product iteration, advance clinical registration, expand its commercial footprint, and explore innovative technologies.

Behind the vast market space lies an urgent clinical need waiting to be met. Breakthrough advancements in therapeutic brain-computer interface (BCI) technology are giving rise to an emerging blue ocean market worth hundreds of billions. Amid increasingly fierce competition, Neurodome is establishing itself as a core participant by leveraging its robust technological barriers developed through years of deep focus on TI technology. It is building a world-leading, full-chain closed-loop TI technology platform, reshaping the landscape of non-invasive deep-brain precision neuromodulation, and defining the future direction of the therapeutic BCI industry.